tacrine has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 7 studies
Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.
tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Intact male GPR88 KO mice showed diminished tacrine-induced PD-like tremor and spontaneous hyperlocomotion." | 3.96 | Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia. ( Mannoury-la-Cour, C; Mantas, I; Millan, MJ; Svenningsson, P; Yang, Y; Zhang, X, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Mantas, I | 1 |
| Yang, Y | 1 |
| Mannoury-la-Cour, C | 1 |
| Millan, MJ | 1 |
| Zhang, X | 1 |
| Svenningsson, P | 1 |
| Pinna, A | 1 |
| Bonaventura, J | 1 |
| Farré, D | 1 |
| Sánchez, M | 1 |
| Simola, N | 2 |
| Mallol, J | 1 |
| Lluís, C | 1 |
| Costa, G | 1 |
| Baqi, Y | 1 |
| Müller, CE | 1 |
| Cortés, A | 1 |
| McCormick, P | 1 |
| Canela, EI | 1 |
| Martínez-Pinilla, E | 1 |
| Lanciego, JL | 1 |
| Casadó, V | 1 |
| Armentero, MT | 1 |
| Franco, R | 1 |
| Trevitt, J | 1 |
| Kawa, K | 1 |
| Jalali, A | 1 |
| Larsen, C | 1 |
| Yao, L | 1 |
| Li, W | 1 |
| She, H | 1 |
| Dou, J | 1 |
| Jia, L | 1 |
| He, Y | 1 |
| Yang, Q | 1 |
| Zhu, J | 1 |
| Cápiro, NL | 1 |
| Walker, DI | 1 |
| Pennell, KD | 1 |
| Pang, Y | 1 |
| Liu, Y | 1 |
| Han, Y | 1 |
| Mao, Z | 1 |
| Carlson, BB | 2 |
| Wisniecki, A | 2 |
| Salamone, JD | 2 |
| Fenu, S | 1 |
| Baraldi, PG | 1 |
| Tabrizi, MA | 1 |
| Morelli, M | 1 |
| Rios, C | 1 |
| Lentini, E | 1 |
| Correa, M | 1 |
| Betz, A | 1 |
7 other studies available for tacrine and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Cholinesterase Inhibitors; Corpus Striatum; Dopami | 2020 |
L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Cannabinoid Receptor Antagonists; | 2014 |
Differential effects of adenosine antagonists in two models of parkinsonian tremor.
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Caffeine; | 2009 |
Activation of transcription factor MEF2D by bis(3)-cognitin protects dopaminergic neurons and ameliorates Parkinsonian motor defects.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Behav | 2012 |
Local injections of the 5-hydroxytryptamine antagonist mianserin into substantia nigra pars reticulata block tremulous jaw movements in rats: studies with a putative model of Parkinsonian tremor.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Injections; | 2003 |
Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions.
Topics: Adenosine A2 Receptor Antagonists; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Anima | 2004 |
Dopamine agonists suppress cholinomimetic-induced tremulous jaw movements in an animal model of Parkinsonism: tremorolytic effects of pergolide, ropinirole and CY 208-243.
Topics: Analysis of Variance; Animals; Cholinergic Agents; Disease Models, Animal; Dopamine Agonists; Dose-R | 2005 |